A federal judge ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved must be made public.
Concern about clinical trial transparency, or more accurately the lack of transparency, is an ongoing problem. A new report shows that the lack of transparency also extends to post-marketing commitments that companies agreed to, following regulatory approval of a drug.
